

AD-A132 484 PREPARATION OF HI-6 HGG-12 AND TOXOGONIN(U) SRI
INTERNATIONAL MENLO PARK CA M A GEIGEL ET AL. MAR 83
DAMD17-82-C-2073

AD-A132 484 PREPARATION OF HI-6 HGG-12 AND TOXOGONIN(U) SRI
INTERNATIONAL MENLO PARK CA M A GEIGEL ET AL. MAR 83
DAMD17-82-C-2073


AD-A132 484 PREPARATION OF HI-6 HGG-12 AND TOXOGONIN(U) SRI 1/1
INTERNATIONAL MENLO PARK CA M A GEIGEL ET AL. MAR 83
DAMD17-82-C-2073

UNCLASSIFIED F/G 7/3

UNCLASSIFIED F/G 7/3

UNCLASSIFIED F/G 7/3 NL

[illegible]



MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS - 1963 - A

AD A132484

AD _____

12

PREPARATION OF HI-6, HGG-12 AND TOXOGONIN

ANNUAL REPORT NO. 1

M. A. Gelgel and M. M. Broussard

March 1983

Supported by

Acquisition Division
U. S. Army Medical Research and Development Command
Fort Detrick, Frederick, Maryland 21701

Contract No. DAMD17-82-C-2073

SRI International
333 Ravenswood Avenue
Menlo Park, California 94025

DTIC
ELECTE
SEP 16 1983
S B D

Contracting Officer's Technical Representative:
H. A. Musallam
Walter Reed Army Institute of Research
Washington, DC 20012

Approved for public release; distribution unlimited.

DISCLAIMER

The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision unless designated by other documentation.

DTIC FILE COPY

88 09 08 004

| REPORT DOCUMENTATION PAGE | | READ INSTRUCTIONS BEFORE COMPLETING FORM | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 1. REPORT NUMBER | | 2. GOVT ACCESSION NO. | |
| 4. TITLE (and Subtitle) | | 3. RECIPIENT'S CATALOG NUMBER | |
| Preparation of HI-6, HGG-12 and Toxogonin | | 5. TYPE OF REPORT & PERIOD COVERED | |
| | | Annual Report No. 1 15 March 1982- 15 March 1983 | |
| 7. AUTHOR(s) | | 6. PERFORMING ORG. REPORT NUMBER | |
| M. A. Geigel and M. M. Broussard | | Annual Report No. 1 PYJ 4168 | |
| 9. PERFORMING ORGANIZATION NAME AND ADDRESS | | 8. CONTRACT OR GRANT NUMBER(s) | |
| SRI International 333 Ravenswood Avenue Menlo Park, CA 94025 | | DAMD17-82-C-2073 | |
| 11. CONTROLLING OFFICE NAME AND ADDRESS | | 10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS | |
| Acquisition Division US Army Medical Research and Development Command Fort Detrick, Frederick, MD 21701 | | 12. REPORT DATE | |
| | | March 1983 | |
| | | 13. NUMBER OF PAGES | |
| 14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office) | | 15. SECURITY CLASS (of this report) | |
| | | Unclassified | |
| | | 15a. DECLASSIFICATION/DOWNGRADING SCHEDULE | |
| 16. DISTRIBUTION STATEMENT (of this Report) | | | |
| Approved for public release. | | <div style="border: 1px solid black; padding: 5px; text-align: center;"> DISTRIBUTION STATEMENT A Approved for public release Distribution Unlimited </div> | |
| 17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report) | | | |
| 18. SUPPLEMENTARY NOTES | | | |
| 19. KEY WORDS (Continue on reverse side if necessary and identify by block number) | | | |
| 1-(4-aminocarboxypyridinio)methoxymethyl-2-hydroxyiminomethyl pyridinium dichloride (HI-6) | | Synthesis | |
| 1,3-bis(4-hydroxyiminomethylpyridinium)dimethyl ether dichloride (Toxogonin) | | Purification | |
| 20. ABSTRACT (Continue on reverse side if necessary and identify by block number) | | | |
| <p>Published procedures for synthesis of HI-6 result in a difficult-to handle intermediate, and a product contaminated with symmetrical impurities. Because of these contaminant, purification requires repeated recrystallizations and leads to substantial material losses. We have discovered two methods that result in acceptable quality HI-6. Neither of these methods is optimized, however, and overall yields are low. We currently have 1150 g of 85% pure HI-6, prepared according to Good Manufacturing Practices (GMP).</p> | | | |

Unclassified

SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)

20. The preparation of Toxogonin is much easier than that of HI-6 because the former is symmetrical. We have 680 g of 99% pure and 400 g of 94% pure Toxogonin prepared according to GMP.

| | |
|--------------------|--------------------------------------------|
| Accession For | |
| NTIS GRA&I | <input checked="checked" type="checkbox"/> |
| DTIC TAB | <input type="checkbox"/> |
| Unannounced | <input type="checkbox"/> |
| Justification | |
| PER JS | |
| By | |
| Distribution | |
| Availability Codes | |
| Dist | Avail and/or Special |
| A | |



Unclassified

SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)


SUMMARY

Published procedures for synthesis of HI-6 result in a difficult-to-handle intermediate, and a product contaminated with symmetrical impurities. Because of these contaminants, purification requires repeated recrystallizations and leads to substantial material losses. We have discovered two methods that result in acceptable quality HI-6. Neither of these methods is optimized, however, and overall yields are low. We currently have 1150 g of 85% pure HI-6, prepared according to Good Manufacturing Practices (GMP).

The preparation of Toxogonin is much easier than that of HI-6 because the former is symmetrical. We have 680 g of 99% pure and 400 g of 94% pure Toxogonin prepared according to GMP.

INTRODUCTION

The objective of this study is to prepare 1 kg each of 1-(4-aminocarboxypyridinio)methoxymethyl-2-(hydroxyiminomethyl)pyridinium dichloride (HI-6), 1-(3-benzoylpyridinio)methoxymethyl-2-(hydroxyiminomethyl)pyridinium dichloride (HGG-12), and 1,3-bis(4-hydroxyiminomethylpyridinium) dimethyl ether dichloride (Toxogonin) in greater than 99% purity according to Good Manufacturing Practices (GMP). These materials are being prepared by the general schemes shown below:



SYNTHESIS

Bis-Chloromethyl Ether (BCME)

Containment. BCME is prepared¹ and reacted in a sealed glassware system ultimately vented through a series of caustic liquid traps. The system was designed with valves, stopcocks, and pumps to allow all manipulations of BCME without opening the system. This design conforms with the Occupational Safety and Health Administration (OSHA) definition of a closed system.

The glassware system is contained within a 1/2-inch, clear, polyvinyl chloride (PVC) glovebox that measures 5 x 3 x 4 feet and constitutes an isolated system as defined by OSHA. We considered many construction materials, and chose PVC because it offered the best combination of chemical resistance to acids, bases, and organic solvents; strength; visibility; non-permeability to BCME; and cost.

The glove box interior is maintained at a slightly lower pressure than the outside work area to further minimize the possibility of operator exposure to BCME. The glove box atmosphere is scrubbed with base before it is exhausted. Because of the pressure differential and the potential for implosion, a removable frame of 2-inch angle aluminum provides additional support for the glovebox.


Under normal operating conditions, a blower provides the pressure differential, and a continuous stream of air is allowed to enter the glovebox through a 2-inch ball valve. A small concentration of ammonia is maintained in the atmosphere. In the event of BCME contamination of the glove box atmosphere, large amounts of ammonia will be admitted to the box to destroy the BCME immediately. The glove box will then be flushed clean of any residual BCME by completely opening the blower valve to the scrubber and a matching air inlet valve. The glove box and its accessories were designed and built by SRI.

Use of Crude BCME. We determined in initial experiments that crude, undried BCME may be used. No significant impurities attributable to the quality of BCME have been observed. The ability to use crude BCME is


important because it eliminates the need for distillation, which complicates the handling of BCME and greatly increases the hazard associated with the process, particularly at large scale-up.

Exploratory Experiments

Hagedorn's conditions²⁻⁴ for preparation of HI-6 yielded Z-2 as a sticky intermediate, that could neither be transferred nor filtered and washed. The resulting HI-6 was contaminated with the symmetrical analogs bis-aldoxime--1,3-bis(2-hydroxyiminomethylpyridinium) dimethyl ether dichloride (I)--and bis-isonicotinamide--1,3-bis-(4-aminocarboxypyridinium) dimethyl ether dichloride (II)--as shown below.



Bis-2-Aldoxime



Bis-Isonicotinamide

Because these impurities are structurally similar to the target compound, it is difficult to separate them. Consequently, purification of HI-6 becomes a major problem and results in substantial product losses.

We conducted exploratory runs (>30-g scale) to determine suitable conditions for preparation of HI-6. The results of the most significant runs are summarized in Table 1. Although bis-aldoxime and bis-isonicotinamide were observed in all experiments, we discovered two methods for preparing acceptable quality HI-6.

The first method involves adding excess BCME to pyridine-2-aldoxime. The use of excess BCME minimizes the formation of bis-2-aldoxime, and appropriate washing of intermediate Z-2 minimizes the formation of the bis-isonicotinamide that forms from unreacted BCME. (Compare Runs 28, 29, and 31.) In Run 31, 40% HI-6 was obtained; the product consisted of HI-6, bis-2-aldoxime, and bis-isonicotinamide in a ratio of 10:1:1.

The second method involves the slow addition of pyridine-2-aldoxime to BCME. This is the reverse of the addition method described in the literature.² (Compare Runs 29 and 33.) To promote complete reaction of BCME (Step 1) so that none remains to form bis-isonicotinamide, we studied the use of an excess of pyridine-2-aldoxime (Runs 41-43). Although some bis-2-aldoxime forms because it is favored by the use of excess pyridine-2-aldoxime, this impurity is easier to remove by recrystallization than bis-isonicotinamide. As expected, the product from these runs contained less bis-isonicotinamide than products from previous runs.

Bis-isonicotinamide is formed from unreacted BCME adhering to or occluded in the crystals of intermediate Z-2. To minimize formation of bis-isonicotinamide, we tried repeated and rigorous washing of Z-2 (Runs 37 and 40) and vacuum drying overnight (Run 38) to remove unreacted BCME; however, the products of these three runs still contained 2-6% bis-isonicotinamide. Protic solvents, which react with BCME, also react with Z-2. When we washed with methanol in Run 40, a low yield was observed.

We also considered recrystallization as a means of removing unreacted

TABLE 1. PREPARATION OF HI-6, CHCl_3 /DMF METHOD

| Run | BCME | pyridine-2-aldoxime | isonicotinamide | Step 1: BCME + pyridine-2-aldoxime \rightarrow 2-2 | | | Mode of Addition ^b | Comments | Crude Yield (%) | Composition of Crude HI-6 (%) | | | Yield of HI-6 (%) |
|-----|------|---------------------|-----------------|------------------------------------------------------|-----------|-----------------------------|-------------------------------|----------------------------------------------------------------|-----------------|-------------------------------|----------------|-----------------|-------------------|
| | | | | CHCl_3 (ml) | Time (hr) | Temp ($^{\circ}\text{C}$) | | | | HI-6 | Bis-2-aldoxime | Isonicotinamide | |
| 21 | 0.05 | 0.05 | 0.05 | 125 | 1 | 45 | Lit | d | 76 | 9 | 19 | 33 | 7 |
| 18 | 0.05 | 0.05 | 0.05 | 125 | 2 | 45 | Lit | d | 73 | 15 | 28 | 6 | 11 |
| 29 | 0.05 | 0.05 | 0.05 | 125 | 4 | 45 | Lit | Hagedorn conditions | 20 | 25 | 27 | 34 | 12 |
| 28 | 0.07 | 0.05 | 0.05 | 125 | 4 | 45 | Lit | | 17 | 63 | 22 | 6 | 15 |
| 31 | 0.1 | 0.05 | 0.05 | 125 | 4 | 45 | Lit | | 86 | 45 | 4 | 5 | 39 |
| 33 | 0.05 | 0.05 | 0.05 | 175 | 4 | 45 | Reverse over 1/2 hr | | 18 | 87 | 8 | 12 | 16 |
| 37 | 0.05 | 0.05 | 0.05 | 75 | 4 | 45 | Lit | 2-2 washed with DMF | 13 | 57 | 14 | 6 | 7 |
| 38 | 0.05 | 0.05 | 0.05 | 125 | 4 | 45 | Lit | 2-2 vacuum dried | 44 | 39 | 8 | 6 | 17 |
| 40 | 0.05 | 0.05 | 0.025 | 75 | 4 | 45 | Lit | 2-2 washed with MeOH and acetone | 10 | 24 | 43 | 2 | 2 |
| 41 | 0.05 | 0.07 | 0.05 | 225 | 4 | 45 | Reverse over 2 hr | | 15 | 54 | 6 | 3 | 8 |
| 42 | 0.05 | 0.07 | 0.05 | 225 | 6 | 60 | Reverse over 4 hr | | 31 | 81 | 1 | 5 | 25 |
| 43 | 0.05 | 0.1 | 0.05 | 325 | 4 | 45 | Reverse over 2 hr | | 43 | 55 | 3 | 6 | 24 |
| 36 | 0.1 | 0.05 | 0.05 | 125 | 4 | 45 | Lit | | 57 | 34 | 9 | 3 | 19 |
| 32 | 0.05 | 0.05 | 0.05 | 75 | 4 | 45 | Lit | | 96 | 34 | 22 | 6 | 33 |
| 39 | 0.05 | 0.05 | 0.05 | 25 ml CHCl_3 + 30 ml DMF | 2 | 45 | Reverse over 2 hr | Isonicotinamide added to BCME; intermediate reacted with oxime | 57 | 2 | 0 | 60 | |

^a2-2 was filtered, washed with 3 x 50 ml chloroform, and reacted with isonicotinamide in 250 ml DMF for 2 hr at 45 $^{\circ}\text{C}$.


^b"Lit." signifies BCME was added to oxime over 10 min; "reverse" signifies oxime added to BCME.

^cCrude yield 15% yield HI-6.

^dFiltered and washed 2-2 was added to clean reaction flask.

BCME. Although recrystallization of Z-2 is reported to cause its decomposition,⁵ we tried test-tube-scale purifications without success. For example, 1 mg of Z-2 was not soluble in 1 ml of dimethyl formamide, tetrahydrofuran, dioxane, acetonitrile, or nitromethane; Z-2 was soluble in dimethyl sulfoxide, but it could not be reprecipitated by acetone dilution.

Another way to address the problem of residual BCME caused by the sluggish reaction of pyridine-2-aldoxime with BCME is to reverse the order of substitution and add isonicotinamide slowly to excess BCME (Run 39). We hypothesized that the rapid reaction of isonicotinamide with BCME would mean that no isonicotinamide would be available to react with the mono-isonicotinamide-substituted BCME (Y-2) whose structure is shown below.



Y-2

This hypothesis would be correct if the reaction of Y-2 with isonicotinamide is slower than the reaction of BCME with isonicotinamide, or if Y-2 precipitated before it can react further. Any residual BCME left in Y-2 after filtering and washing would yield, in Step 2, bis-2-aldoxime, which is easier to remove. Our results did not, however, bear out the hypothesis. Bis-isonicotinamide was the major product isolated from Run 29.

To determine whether isonicotinamide is displacing the pyridine-2-aldoxime portion of HI-6 to give bis-isonicotinamide, we heated HI-6 and isonicotinamide in dimethylformamide (DMF) for 2 hr at 45°C. No formation of bis-isonicotinamide was observed.

A comparison of Runs 29 and 32 shows the effect of reactant concentration. As expected, higher concentrations result in higher yields. Unfortunately, for the preferable reverse addition method, the amount of chloroform used is governed by the solubility of pyridine-2-

aldoxime, especially when it is added at room temperature through a dropping funnel. In larger scale and process work, we could add more concentrated, hot solutions through metering pumps. A high yield in Step 1 means a small amount of residual BCME; consequently, a smaller amount of bis-isonicotinamide was observed in Run 32. The substantial amount of bis-2-aldoxime obtained in that run is common when a stoichiometric amount of BCME is added to the oxime.

Runs 31 and 36 illustrate the reproducibility of our technique. The most difficult part of the method to reproduce is the washing of Z-2.

One-Solvent-System

Because of the difficulty in handling Z-2, we explored an alternative to the two step-two solvent (CHCl_3/DMF) procedure: We prepared Z-2 in DMF solvent and, without isolating the Z-2, we added isonicotinamide. This route offers the great advantages of simplicity and minimal need for manipulation of BCME-containing streams. However, in all cases in which we used this system (see Table 2), significant quantities of bis-isonicotinamide were formed. Although we believe it is possible to adjust stoichiometry, time, and temperature to optimize HI-6 formation and minimize by-product formation, we did not explore this route further because the project goal is to prepare material and not to develop a process.

Table 2. PREPARATION OF HI-6, ALL DMF METHOD

| Run | Conditions ^a | | Yield (%) | Crude HI-6 (%) | | |
|-----|-------------------------|----------------|-----------|----------------|----------------|---------------------|
| | DMF in Step 1 (mL) | Time (hr) | | HI-6 | Bis-2-Aldoxime | Bis-isonicotinamide |
| 12 | 25 | 0.75 | 67 | 22 | 0 | 25 |
| 24 | 100 | 1.5 | 56 | 23 | 0 | 55 |
| 22 | 200 | 1.5 | 50 | 8 | 0 | 67 |
| 19 | 200 | 3 | 17 | 3 | 0 | 90 |
| 25 | 100 | 3 | 56 | 21 | 1 | 39 |
| 27 | 100 | 3 ^b | 67 | 29 | 5 | 37 |

^a0.05 mole BCME was added to 0.05 mole pyridine 2-aldoxime in the specified amount of DMF, and heated at 45°C for the specified time; 0.05 mole isonicotinamide in 50 mL DMF was then added to the reaction mixture, which was heated at 45°C for the specified time.

^bReaction mixture was heated at 60°C; Run 26, heated at 80°C, turned black.

PRODUCTION

HI-6

For production of HI-6, we chose Method 1, the slow addition of excess BCME to pyridine-2-aldoxime. We chose this method over Method 2 for two reasons: (1) BCME is relatively easy to synthesize, whereas pyridine-2-aldoxime is expensive; (2) In our closed system the addition of solids is difficult. The feasible scale of reaction using Method 2 is then governed by the limited solubility of pyridine-2-aldoxime in the chloroform solvent.

The current inventory of HI-6 is 1154 g of 85% pure material as shown in Table 3.

Table 3

INVENTORY OF HI-6

| <u>Source (Pilot Plant Run No.)</u> | <u>Quantity (g)</u> | <u>Average Purity (%)</u> |
|-------------------------------------|---------------------|---------------------------|
| P3, 8, 10, 11, | 326 | 87 |
| P14, 15 | 290 | 80 |
| P16 | 141 | 85 |
| P17 | 178 | 82 |
| P19 | 82 | 85 ^a |
| P20 | 64 | 85 ^a |
| P21 | 73 | 85 ^a |
| Total | <u>1153</u> | |

a) Analysis by nuclear magnetic resonance (nmr); other analyses are by high pressure liquid chromatography (hplc).

Given the results of initial, small-scale recrystallizations, we expect to recover ~900 g of 99% HI-6 (~75% recovery).

Notable in Table 3 are the decreased yields in Runs P19-21. In these runs we found larger amounts of the sticky material always formed with the intermediate Z-2. In Run P18, the sticky material predominated, and the isolated final product was mostly bis-2-aldoxime. In Run P19, the crystalline Z-2 was separated from the sticky material, and the two fractions were treated separately in the usual manner. The former fraction yielded HI-6 of acceptable quality, but in decreased yield; the latter fraction yielded mostly bis-aldoxime. We postulate that the sticky material is predominantly bis-aldoxime that contains some Z-2 and some unreacted BCME. Its formation may be a complex function of the rate of addition of BCME, the form and rate of precipitation of Z-2, stirring rate, temperature of pyridine-2-aldoxime solution when BCME is added, and other, subtle, unidentified factors.

The conditions being used are by no means optimized, and the aspects of the reaction scheme that present problems include:

- Handling of Z-2. This intermediate has varied from a sticky material that adheres to the stirring rod to a very hard solid that is difficult to remove from the flask.
- Washing of Z-2. The physical form of Z-2 makes washing difficult, yet incomplete washing results in the difficult-to-remove bis-isonicotinamide impurity.
- Product color. The crude product ranges from light to dark gray, and is sometimes green.
- Sensitivity to operator. Production Run 7, conducted by a different operator, yielded poor results.
- Variation in ratio of HI-6 to impurities.
- Corrosion of equipment and resulting malfunction caused by HCl and ammonia fumes inside the glove box. Ammonia vapors are used to react with any escaped BCME.
- Substantial recrystallization losses (~50%) through attempts to remove small amounts (<5%) of impurities and traces of color.
- Poor and Variable yields.

Toxogonin

Because Toxogonin is a symmetrical molecule, its preparation does not present the problems of by-product formation encountered with HI-6. Our present inventory includes 680 g of 99% Toxogonin. We expect that recrystallization of an additional 400 g of 94% Toxogonin will yield ~320 g of 99% material. A final recrystallization will be performed to combine all fractions into a homogeneous lot.

HGG-12

Preparation of HGG-12 will begin in the next quarter.

PURIFICATION

Because even the best synthesis scheme tried to date produces HI-6 contaminated with some symmetrical analogs, a suitable purification method was required. Although recrystallization is the preferred technique, we also investigated the possibility of using ion exchange, adsorptive, and high-pressure liquid chromatography (hplc).

Recrystallization

Because crude, vacuum-dried material inevitably contains residual DMF solvent, the first purification step consists of a precipitation. Because BCME is hydrolyzed by water, precipitation of HI-6 from a water solution has the advantage of assuring that no BCME will be present in the product.

We tested a number of systems for recrystallization of precipitated HI-6:

Water/acetone
Water/methanol
Water/ethanol
Water/iso-propanol
Methanol
Ethanol, 95%
methanol/ether

Pure water was not tested because of the high solubility of HI-6 in that solvent. Conversely, because HI-6 is insoluble in most organic solvents, they cannot be used.

Several solvent systems removed bis-aldoxime, but bis-isonicotinamide proved more difficult to remove. Many solute concentrations and ratios of water to organic solvent were tried; some of these are summarized in Table 4.

For production, recrystallizations are carried out slowly and carefully in 75% ethanol/water, the optimal solvent system. Because HI-6

TABLE 4. RECRYSTALLIZATION OF HI-6

| Sample | HI-6 | Condition | Solvent | Percent Organics ^a | | | |
|--------------|---------------|----------------------------------------------|----------------------------|-------------------------------|------|----------------|---------------------|
| | | | | Yield | HI-6 | Bis-2-aldoxime | Bis-isonicotinamide |
| Crude Run 31 | | | | | | | |
| 31-1 | 15 g crude 31 | 450 ml 89% MeOH/ether ^b | MeOH | 8 | 45 | 4 | 5 |
| 31-2 | 31-1 | | | - | 96 | 0 | 4 |
| | | | | | 97 | 0 | 3 |
| Crude Run 32 | | | | | | | |
| 32-1 | 17 g crude 32 | 650 ml 61% MeOH/ether ^b | 300 ml MeOH | 22 | 34 | 22 | 6 |
| 32-2 | 4 g 32-1 | | | 31 | 81 | 15 | 5 |
| 32-2-1 | 0.2 g 32-2 | 0.4 g 50% MeOH/water | 0.6 g 50% MeOH/water | 80 | 94 | 1 | 5 |
| 32-2-2 | 0.2 g 32-2 | | | 70 | 95 | 0 | 5 |
| 32-2-3 | 0.2 g 32-2 | 0.8 g 50% i-PrOH/water | 0.8 g 50% EtOH/water | 80 | 96 | 0 | 4 |
| 32-2-4 | 0.2 g 32-2 | | | - | 94 | 0 | 5 |
| 32-2-2-1 | 0.08 g 32-2-2 | 1 ml 70% EtOH/water | | 62 | 99 | 0 | 0.5 |
| Crude 36 | | | | | | | |
| 36-1 | 1 g crude 36 | 140 ml Acetone/MeOH/water 5/1/1 ^b | 0.5 g 50% MeOH/water | 10 | 34 | 9 | 3 |
| 36-1-1 | 0.1 g 36-1 | | | 33 | 69 | 25 | 3 |
| 36-1-2 | 0.1 g 36-1 | 0.9 g 66% MeOH/water | 1 g iPrOH/MeOH/water 2/1/1 | 10 | 77 | 19 | 0.5 |
| 36-1-3 | 0.1 g 36-1 | | | 33 | 97 | 2 | 1 |
| 36-1-4 | 0.1 g 36-1 | 1 g 50% MeOH/water/3% HCl | 1 g iPrOH/MeOH/water 1/1/2 | 19 | 84 | 12 | 1 |
| 36-1-5 | 0.1 g 36-1 | | | 60 | 74 | 26 | 0.5 |
| | | | | | 80 | 19 | 1 |
| Crude 37 | | | | | | | |
| 37-1 | 2 g crude 37 | 150 ml 66% MeOH/ether ^b | 23 ml 87% MeOH/water | 50 | 57 | 14 | 6 |
| 37-2 crop 1 | 1 g 37-1 | | | 20 | 83 | 9 | 7 |
| 37-2 crop 2 | - | | | 10 | 98 | 1 | 1 |
| | | | | | 93 | 1 | 6 |
| Crude 42 | | | | | | | |
| 42-1 | 6 g crude 42 | 250 ml 80% MeOH/water ^b | 40 ml 75% EtOH/water | 59 | 81 | 1 | 5 |
| 42-2 | 3 g 42-1 | | | 58 | 96 | 0 | 4 |
| 42-3 | 1.7 g 42-2 | 20 ml 75% EtOH/water | | 50 | 99 | 0 | 0.5 |

^aCertain samples have water of hydration.^bPrecipitation, not true recrystallization.

decomposes in solution, recrystallizations are carried out at pH 3-4, the range of maximum stability. Charcoal treatment is used to remove color.

Ion Exchange Chromatography

HI-6, bis-2-aldoxime, and bis-isonicotinamide differ most prominently in the number of oxime and amide functionalities they contain. We decided to capitalize on this feature to separate the compounds by ion exchange chromatography. When the oxime is in its anion form, bis-aldoxime, HI-6, and bis-isonicotinamide are neutral, a monochloride salt, and a dichloride salt, respectively.

A cation exchange resin may be effective in separating HI-6 from its symmetrical analogs, especially in removing bis-isonicotinamide. The results of our attempts are summarized in Table 5. Percentage recovery of HI-6 has not yet been determined, and some decomposition of HI-6 is anticipated at higher pH levels.

Although recrystallization is the simplest way to purify the required material, if chromatography is required, ion exchange would be preferred for several reasons: First, the amount of resin required is only 3-5 times the amount of material to be purified (as opposed to 50-100 times for silica gel or alumina). Second, the resin can be regenerated. Third, ion exchange chromatography is faster than adsorptive chromatography.

Adsorptive Chromatography

HI-6 may be separated from bis-isonicotinamide by silica gel thin layer chromatography using 15% aqueous sodium chloride/methanol at a ratio of 5:1. With this solvent system and silica dry column chromatography, we obtained HI-6 free of organic impurities, but contaminated with sodium chloride from the elution solvent. Suitable silica gel or alumina conditions free of sodium chloride have not been found. Conditions for hplc require the use of an ion-pairing reagent, which would also contaminate the eluted HI-6.

TABLE 5. PURIFICATION OF HI-6 BY ION EXCHANGE^a CHROMATOGRAPHY

| Sample | Conditions ^b | Percent | | |
|--------|---------------------------------------------------|---------|----------------|---------------------|
| | | HI-6 | Bis-2-aldoxime | Bis-isonicotinamide |
| 38-1 | 35 mg HI-6 | 80 | 12 | 6 |
| 38-6-3 | { 35 mg HI-6; 0.5 g resin } | 77 | 18 | 1 |
| 38-6-4 | | 89 | 7 | 0.5 |
| 38-6-5 | | 76 | 20 | 0.7 |
| 38-6-6 | | 61 | 31 | 1.4 |
| 38-7-2 | { 1 g HI-6 3 g resin } | 96 | 3 | 0.5 |
| 38-7-2 | | 98 | 1 | 0.1 |
| 38-7-4 | | 89 | 7 | 2 |
| 38-7-5 | | 88 | 6 | 3 |
| 38-8-1 | { 35 mg HI-6 brought to pH 8; 0.5 g resin } | 5 | 62 | 19 |
| 38-8-2 | | 74 | 13 | 0 |
| 38-8-3 | | 36 | 8 | 0 |

^aBio-Rex 70 cation exchange resin.

^bElute with water.

Analytical Methods

Table 6 outlines various hplc conditions reported for the analysis of HI-6. Separation of all important components is possible, as illustrated in Figure 1. Propiophenone is used as the internal standard. The use of a new column and modified conditions have solved initial problems of unacceptable resolution, retention time shifts, and nonreproducibility.

TABLE 6. CONDITIONS FOR HPLC ANALYSIS OF HI-6 AND TOXOGONIN

| Benschop Paper ^a | | Contract DAMD17-79-C-9154 | Contract DAMD17-82-C-2073 |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| | | SRI Project 8906 ^b | SRI Project 4168 |
| Instrument | Waters Associate Model 6000A | Waters Associate Model 6000A | Spectra Physics 3500B |
| Detector | Tracov 970 A; 304 nM | Perkin Elmer LC-75; 300 nM | Chromatronix 225; 254 nM. |
| Column | RP-18; 5 microns | Waters RCM-CN; 10 microns | Waters μ -Bondapak CN; 10 microns |
| Mobile phase | 30% methanol/70% 0.1 M sodium acetate buffer (pH 4.80) with 4.6 mM sodium n-octanesulfonate and 0.3 mM dimethyl octylamine | 30% Methanol/70% 0.1 M KH_2PO_4 (pH 7.1) | 10% Acetonitrile/ 90% 0.025 M sodium pentanesulfonate |
| Flowrate | 0.2 ml/min | 1.5 ml/min | 1.0 ml/min |
| Integrated | LDC-304-50 computing integrator | Hewlett-Packard 3390A | Hewlett-Packard 3380A |

^aHendrick P. Benschop, et al., Journal of Chromatography, 225, 107 (1981).^bReport No. 404.

Table 4. CONDITIONS FOR HPLC ANALYSIS OF HI-6 AND TOXOGONIN




Figure 1. HPLC SEPARATION OF IMPORTANT SYSTEM COMPONENTS

REFERENCES

1. S. Buc, Org. Syn., Coll. Vol. IV, 101 (1963).
2. I. Hagedorn (to Merck), "Bis-quaternary Pyridinium Salts," U.S. Patent 3,852,294 (December 3, 1974).
3. I. Hagedorn (to Merck), "Bis-quaternary Pyridinium Salts," U.S. Patent 3,773,775 (November 20, 1973).
4. I. Hagedorn (to Merck), "Bis-quaternary Pyridium-2-Aldoxime and their Preparation," German Patent 26 16 481 (November 3, 1977).
5. K. Schoene, "Darstellung und Untersuchung neuer Acetylcholinesterase-Reaktivatoren," Dissertation, University of Freiburg (1967).

DISTRIBUTION

| | <u>No. of Copies</u> |
|-------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Director Walter Reed Army Institute of Research ATTN: SGRD-UWZ-C Walter Reed Army Medical Center Washington, DC 20012 | 5 |
| Commander US Army Medical Research and Development Command ATTN: SGRD-RMS Fort Detrick Frederick, MD 21701 | 4 |
| Administrator Defense Technical Information Center ATTN: DTIC-DDA Cameron Station Alexandria, VA 22314 | 12 |
| Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234 | 1 |
| Dean, School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20014 | 1 |

DATE
FILMED
8